Editas Medicine Inc. (EDIT)
Editas Medicine, Inc. (EDIT) Barclays 27th Annual Global Healthcare Conference (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT ) Barclays 27th Annual Global Healthcare Conference March 11, 2025 9:00 AM ET Company Participants Gilmore O'Neill - President and Chief Executive Officer Erick Lucera - Executive Vice President and Chief Financial Officer Conference Call Participants Gena Wang - Barclays Gena Wang Good morning, everyone. My name is Gena Wang, I'm [Indiscernible] at Biotech Analyst at the Barclays.
Editas Medicine, Inc. (EDIT) Leerink Partners Global Healthcare Conference (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT ) Leerink Partners Global Healthcare Conference March 10, 2025 9:20 AM ET Company Participants Gilmore O'Neill - President & CEO Erick Lucera - EVP and CFO Unidentified Company Representative Welcome to Leerink Global Healthcare Conference 2025. So this morning, we are, discussing with the Editas Management Team, and we have Erick Lucera, and we have, Gilmore O'Neill with us.
Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
EDIT stock is down following the announcement of dismal fourth-quarter 2024 results as both earnings and revenues miss estimates.
Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates
Editas Medicine (EDIT) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.23 per share a year ago.
Editas Medicine, Inc. (EDIT) TD Cowen 45th Annual Health Care Conference Transcript
Editas Medicine, Inc. (NASDAQ:EDIT ) TD Cowen 45th Annual Health Care Conference March 3, 2025 2:30 PM ET Company Participants Gilmore O'Neill - Chief Executive Officer Erick Lucera - Chief Financial Officer Conference Call Participants Alexander Kelly - TD Cowen Alexander Kelly Hi everyone. I'm Alex Kelly.
Editas Medicine, Inc. (EDIT) 43rd Annual JPMorgan Healthcare Conference - (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT ) 43rd Annual JPMorgan Healthcare Conference Call January 15, 2025 2:15 PM ET Company Participants Gilmore O'Neill - President and Chief Executive Officer Linda Burkly - Executive Vice President and Chief Scientific Officer Erick Lucera - Executive Vice President and Chief Financial Officer Conference Call Participants Brian Cheng - JPMorgan Brian Cheng Good morning. Thanks for joining us for another session at the 43rd JPMorgan Healthcare Conference.
EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce
Editas stock falls as it ends development of reni-cel for SCD and TDT following failed attempts to find a commercial partner. It plans to cut workforce by 65%.
Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026
On Thursday, Editas Medicine Inc. EDIT announced a strategic realignment to focus on in vivo gene editing.
Editas to reduce about 65% of its workforce over the next six months
Editas Medicine said on Thursday it would cut around 180 jobs, representing 65% of its workforce, over the next six months as part of the company's transition towards becoming a developer of therapies that edit genes within the body.
Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock?
Editas Medicine, Inc. (EDIT) 7th Annual Evercore HealthCONx Conference (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT ) 7th Annual Evercore HealthCONx Conference December 3, 2024 1:20 PM ET Company Participants Erick Lucera - Executive Vice President and Chief Financial Officer Cristi Barnett - Senior Vice President, Corporate Communications and Investor Relations Conference Call Participants Liisa Bayko - Evercore ISI Liisa Bayko Okay, welcome everyone. This is Evercore's Healthcare Conference.
Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts
BofA Securities downgraded Editas Medicine Inc EDIT, citing few value-driving catalysts in the near term.
